Vorbipiprant sodium

N/A

Report date: 2024/10/30 17:01:34
NME

Base Information

Drug NameVorbipiprant sodium
Drug Alias NameCR-6086CR-5790
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProstanoid EP4 receptor antagonists
TargetsProstanoid EP4 receptor
Therapy Area/IndicationsSolid tumoursArthritis, RheumatoidStomach Neoplasms +[4
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaItaly
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesRottapharm Biotech Srl
China Registration ClassN/A

Develop Information

Active CompaniesRottapharm Biotech Srl
Inactive CompaniesN/A
Active IndicationsSolid tumoursStomach NeoplasmsColorectal Neoplasms
Inactive IndicationsArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A